Cencora CFO James Cleary to Retire
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy COR?
Source: NASDAQ.COM
- Executive Retirement: Cencora, Inc. announced that CFO and Executive Vice President James Cleary will retire on June 30, marking a significant leadership change that may impact investor confidence.
- Successor Search: The company is actively seeking a successor for Cleary, demonstrating its commitment to future leadership and ensuring continuity and stability in financial management.
- Transition Support: Cleary will serve in an advisory role until the end of 2026 to assist with the transition, aiming to mitigate potential risks associated with executive turnover.
- Stock Price Volatility: Following the retirement announcement, Cencora's shares fell 3.29% in pre-market trading on the New York Stock Exchange, reflecting market concerns regarding the leadership change.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy COR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on COR
Wall Street analysts forecast COR stock price to rise
9 Analyst Rating
8 Buy
1 Hold
0 Sell
Strong Buy
Current: 345.880
Low
400.00
Averages
415.38
High
440.00
Current: 345.880
Low
400.00
Averages
415.38
High
440.00
About COR
Cencora, Inc. is a global pharmaceutical sourcing and distribution services company. The Company helps both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. The Company operates through two segments: U.S. Healthcare Solutions and International Healthcare Solutions. The U.S. Healthcare Solutions segment distributes a comprehensive offering of brand-name, specialty brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a variety of healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, long-term care and alternate site pharmacies, and other customers. The International Healthcare Solutions segment consists of businesses that focus on international pharmaceutical wholesale and related service operations and global commercialization services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cencora CFO James Cleary to Retire
- Executive Retirement: Cencora, Inc. announced that CFO and Executive Vice President James Cleary will retire on June 30, marking a significant leadership change that may impact investor confidence.
- Successor Search: The company is actively seeking a successor for Cleary, demonstrating its commitment to future leadership and ensuring continuity and stability in financial management.
- Transition Support: Cleary will serve in an advisory role until the end of 2026 to assist with the transition, aiming to mitigate potential risks associated with executive turnover.
- Stock Price Volatility: Following the retirement announcement, Cencora's shares fell 3.29% in pre-market trading on the New York Stock Exchange, reflecting market concerns regarding the leadership change.
See More
Cencora CFO James F. Cleary to Retire in 2026 After Seven Years
- Executive Retirement Announcement: Cencora's CFO James F. Cleary will retire on June 30, 2026, after over seven years in the role, during which the company maintained financial stability, potentially impacting future financial strategies.
- Transition Support Plan: Cleary will remain in an advisory role until the end of the year to assist with the transition to a new CFO, ensuring continuity and stability in the company's financial management.
- Successor Search Initiated: Cencora has begun the search for Cleary's successor, considering both internal and external candidates, indicating the company's commitment to executive selection and aiming to maintain its growth momentum.
- Financial Guidance Reaffirmed: Cencora reaffirmed its fiscal 2026 adjusted diluted earnings per share guidance midpoint of $17.60, reflecting confidence in future performance, despite market consensus being slightly higher at $17.62, indicating robustness in financial expectations.
See More
Cencora Reaffirms Fiscal 2026 Financial Guidance
- Executive Retirement Announcement: Cencora has announced that CFO James F. Cleary will retire on June 30, 2026, after over 11 years in leadership, which may impact the company's financial strategy and investor confidence.
- Successor Search Initiated: The company has engaged an executive search firm to evaluate internal and external candidates, with Cleary providing advisory support during the transition to ensure a smooth leadership change, thereby mitigating potential operational risks.
- Financial Guidance Reaffirmed: Cencora reaffirmed its adjusted diluted EPS guidance range of $17.45 to $17.75 for fiscal year 2026, indicating confidence in future performance, which may attract investor interest.
- Company Overview: Cencora is a leading global pharmaceutical solutions organization with over $300 billion in annual revenue, ranked 10th on the Fortune 500, highlighting its strong position and market influence in the industry.
See More
Three Key Sectors to Monitor While the S&P 500 Moves Sideways
Geopolitical Concerns: Ongoing geopolitical issues, including tensions related to Iran and international trade, are impacting market sentiment.
Tech Sector Pressures: The tech sector is facing challenges, particularly due to concerns surrounding artificial intelligence.
Investor Behavior: Instead of withdrawing from equities, investors are shifting their focus within the market.
Market Opportunities: This rotation in investment strategy is creating new pockets of opportunity for investors.
See More
TimesSquare Capital Increases ESAB Holdings by 262,850 Shares
- Share Acquisition Details: On February 6, 2026, TimesSquare Capital Management disclosed an increase of 262,850 shares in ESAB during Q4, representing an estimated trade value of $30.08 million, indicating growing confidence in industrial manufacturing and infrastructure spending.
- Asset Allocation Shift: This acquisition raised ESAB's share to 1.61% of TimesSquare's 13F assets under management, reflecting the firm's strategic focus on this sector and enhancing ESAB's market position.
- Market Performance Analysis: As of February 5, 2026, ESAB shares were priced at $127.90, up 5.3% over the past year but trailing the S&P 500 by 6.8 percentage points, suggesting a cautious market outlook on its future growth.
- Industry Outlook: As a leading provider of welding and cutting solutions with approximately $2.8 billion in annual revenue, ESAB is expected to benefit from ongoing infrastructure investments and manufacturing growth, making it sensitive to economic cycles and government spending priorities.
See More
TimesSquare Capital Increases ESAB Stake by $30 Million
- Share Acquisition Details: On February 6, 2026, TimesSquare Capital Management disclosed the purchase of 262,850 shares of ESAB, representing an estimated trade size of $30.08 million, indicating growing confidence in industrial manufacturing and infrastructure spending.
- Value Increase: Following this transaction, the total value of ESAB shares held rose to $107.15 million, reflecting a $29.35 million increase at quarter-end, showcasing the dual impact of purchasing activity and stock price movements.
- Portfolio Allocation: ESAB accounts for 1.61% of TimesSquare's assets under management, and while it does not rank among the top five holdings, the 38% increase in position suggests a bullish outlook on sectors related to construction and energy projects.
- Industry Outlook: As a leading provider of welding and cutting solutions with approximately $2.8 billion in annual revenue, ESAB is well-positioned to benefit from ongoing infrastructure investments, making it an attractive option for investors sensitive to economic cycles.
See More
Cencora CFO James Cleary to Retire
- Executive Retirement: Cencora, Inc. announced that CFO and Executive Vice President James Cleary will retire on June 30, marking a significant leadership change that may impact investor confidence.
- Successor Search: The company is actively seeking a successor for Cleary, demonstrating its commitment to future leadership and ensuring continuity and stability in financial management.
- Transition Support: Cleary will serve in an advisory role until the end of 2026 to assist with the transition, aiming to mitigate potential risks associated with executive turnover.
- Stock Price Volatility: Following the retirement announcement, Cencora's shares fell 3.29% in pre-market trading on the New York Stock Exchange, reflecting market concerns regarding the leadership change.
See More
Cencora CFO James F. Cleary to Retire in 2026 After Seven Years
- Executive Retirement Announcement: Cencora's CFO James F. Cleary will retire on June 30, 2026, after over seven years in the role, during which the company maintained financial stability, potentially impacting future financial strategies.
- Transition Support Plan: Cleary will remain in an advisory role until the end of the year to assist with the transition to a new CFO, ensuring continuity and stability in the company's financial management.
- Successor Search Initiated: Cencora has begun the search for Cleary's successor, considering both internal and external candidates, indicating the company's commitment to executive selection and aiming to maintain its growth momentum.
- Financial Guidance Reaffirmed: Cencora reaffirmed its fiscal 2026 adjusted diluted earnings per share guidance midpoint of $17.60, reflecting confidence in future performance, despite market consensus being slightly higher at $17.62, indicating robustness in financial expectations.
See More
Cencora Reaffirms Fiscal 2026 Financial Guidance
- Executive Retirement Announcement: Cencora has announced that CFO James F. Cleary will retire on June 30, 2026, after over 11 years in leadership, which may impact the company's financial strategy and investor confidence.
- Successor Search Initiated: The company has engaged an executive search firm to evaluate internal and external candidates, with Cleary providing advisory support during the transition to ensure a smooth leadership change, thereby mitigating potential operational risks.
- Financial Guidance Reaffirmed: Cencora reaffirmed its adjusted diluted EPS guidance range of $17.45 to $17.75 for fiscal year 2026, indicating confidence in future performance, which may attract investor interest.
- Company Overview: Cencora is a leading global pharmaceutical solutions organization with over $300 billion in annual revenue, ranked 10th on the Fortune 500, highlighting its strong position and market influence in the industry.
See More
Three Key Sectors to Monitor While the S&P 500 Moves Sideways
Geopolitical Concerns: Ongoing geopolitical issues, including tensions related to Iran and international trade, are impacting market sentiment.
Tech Sector Pressures: The tech sector is facing challenges, particularly due to concerns surrounding artificial intelligence.
Investor Behavior: Instead of withdrawing from equities, investors are shifting their focus within the market.
Market Opportunities: This rotation in investment strategy is creating new pockets of opportunity for investors.
See More
TimesSquare Capital Increases ESAB Holdings by 262,850 Shares
- Share Acquisition Details: On February 6, 2026, TimesSquare Capital Management disclosed an increase of 262,850 shares in ESAB during Q4, representing an estimated trade value of $30.08 million, indicating growing confidence in industrial manufacturing and infrastructure spending.
- Asset Allocation Shift: This acquisition raised ESAB's share to 1.61% of TimesSquare's 13F assets under management, reflecting the firm's strategic focus on this sector and enhancing ESAB's market position.
- Market Performance Analysis: As of February 5, 2026, ESAB shares were priced at $127.90, up 5.3% over the past year but trailing the S&P 500 by 6.8 percentage points, suggesting a cautious market outlook on its future growth.
- Industry Outlook: As a leading provider of welding and cutting solutions with approximately $2.8 billion in annual revenue, ESAB is expected to benefit from ongoing infrastructure investments and manufacturing growth, making it sensitive to economic cycles and government spending priorities.
See More
TimesSquare Capital Increases ESAB Stake by $30 Million
- Share Acquisition Details: On February 6, 2026, TimesSquare Capital Management disclosed the purchase of 262,850 shares of ESAB, representing an estimated trade size of $30.08 million, indicating growing confidence in industrial manufacturing and infrastructure spending.
- Value Increase: Following this transaction, the total value of ESAB shares held rose to $107.15 million, reflecting a $29.35 million increase at quarter-end, showcasing the dual impact of purchasing activity and stock price movements.
- Portfolio Allocation: ESAB accounts for 1.61% of TimesSquare's assets under management, and while it does not rank among the top five holdings, the 38% increase in position suggests a bullish outlook on sectors related to construction and energy projects.
- Industry Outlook: As a leading provider of welding and cutting solutions with approximately $2.8 billion in annual revenue, ESAB is well-positioned to benefit from ongoing infrastructure investments, making it an attractive option for investors sensitive to economic cycles.
See More
